U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H38O4
Molecular Weight 414.5775
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GESTONORONE CAPROATE

SMILES

CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O

InChI

InChIKey=XURCMZMFZXXQDJ-UKNJCJGYSA-N
InChI=1S/C26H38O4/c1-4-5-6-7-24(29)30-26(17(2)27)15-13-23-22-10-8-18-16-19(28)9-11-20(18)21(22)12-14-25(23,26)3/h16,20-23H,4-15H2,1-3H3/t20-,21+,22+,23-,25-,26-/m0/s1

HIDE SMILES / InChI
Molecular Formula C26H38O4
Molecular Weight 414.5775
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including, http://www.medicamentos.com.mx/DocHTM/22255.htm

Gestonorone is a progesterone analogue indicated for the treatment of benign prostatic hyperplasia and endometrial cancer. The drug is approved in many countries and used under the names Primostat and Depostat.

Originator

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
PRIMOSTAT

Approved Use

Conservative treatment of benign prostatic hyperplasia and palliative treatment of severe endometrial cancer.
Palliative
Approved
8583
PRIMOSTAT

Approved Use

Conservative treatment of benign prostatic hyperplasia and palliative treatment of severe endometrial cancer.
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4.7%
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/1/670109_2479401A1035_1_001_1F.pdf#page=10
GESTONORONE CAPROATE plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
900 mg 3 times / week multiple, intramuscular
Highest studied dose
Dose: 900 mg, 3 times / week
Route: intramuscular
Route: multiple
Dose: 900 mg, 3 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/4097364/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/4097364/
Other AEs: oronary insufficiency, General malaise...
Other AEs:
oronary insufficiency (4%)
General malaise
Chest tightness
Sources:
https://pubmed.ncbi.nlm.nih.gov/4097364/
300 mg 1 times / week multiple, intramuscular
Studied dose
Dose: 300 mg, 1 times / week
Route: intramuscular
Route: multiple
Dose: 300 mg, 1 times / week
Sources:
https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/121731
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/121731
Disc. AE: Pain, Rash...
AEs leading to
discontinuation/dose reduction:
Pain (8%)
Rash (4%)
Impotence (4%)
Sources:
https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/121731
AEs

AEs

AESignificanceDosePopulation
Chest tightness
900 mg 3 times / week multiple, intramuscular
Highest studied dose
Dose: 900 mg, 3 times / week
Route: intramuscular
Route: multiple
Dose: 900 mg, 3 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/4097364/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/4097364/
General malaise
900 mg 3 times / week multiple, intramuscular
Highest studied dose
Dose: 900 mg, 3 times / week
Route: intramuscular
Route: multiple
Dose: 900 mg, 3 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/4097364/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/4097364/
oronary insufficiency 4%
900 mg 3 times / week multiple, intramuscular
Highest studied dose
Dose: 900 mg, 3 times / week
Route: intramuscular
Route: multiple
Dose: 900 mg, 3 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/4097364/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/4097364/
Impotence 4%
Disc. AE
300 mg 1 times / week multiple, intramuscular
Studied dose
Dose: 300 mg, 1 times / week
Route: intramuscular
Route: multiple
Dose: 300 mg, 1 times / week
Sources:
https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/121731
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/121731
Rash 4%
Disc. AE
300 mg 1 times / week multiple, intramuscular
Studied dose
Dose: 300 mg, 1 times / week
Route: intramuscular
Route: multiple
Dose: 300 mg, 1 times / week
Sources:
https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/121731
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/121731
Pain 8%
Disc. AE
300 mg 1 times / week multiple, intramuscular
Studied dose
Dose: 300 mg, 1 times / week
Route: intramuscular
Route: multiple
Dose: 300 mg, 1 times / week
Sources:
https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/121731
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/121731
PubMed

PubMed

TitleDatePubMed
Adjuvant hormonal therapy for stage I endometrial cancer.
2008-06
Gestronol hexanoate (SH582) and benign prostatic hypertrophy.
1972-02
Clinical trial of gestronol hexanoate (SH582) in benign prostatic hypertrophy.
1972-02
Patents

Patents

WO2015092647 A1
2

Sample Use Guides

In Vivo Use Guide
Slow intramuscular injection of 200 mg every week for 2 to 3 months.
Route of Administration: Intramuscular
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:47:11 GMT 2025
Edited
by admin
on Mon Mar 31 17:47:11 GMT 2025
Record UNII
U38E620NS6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEPOSTAT
Preferred Name English
GESTONORONE CAPROATE
INN   JAN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
GESTONORONE CAPROATE [JAN]
Common Name English
NSC-84054
Code English
GESTRONOL HEXANOATE
Common Name English
GESTONORONE HEXANOATE
Common Name English
gestonorone caproate [INN]
Common Name English
GESTONORONE CAPROATE [USAN]
Common Name English
17-Hydroxy-19-norpregn-4-ene-3,20-dione hexanoate
Common Name English
19-NORPREGN-4-ENE-3,20-DIONE, 17-((1-OXOHEXYL)OXY)-
Common Name English
SH-582
Code English
GESTONORONE CAPROATE [MART.]
Common Name English
SH 582
Code English
GESTONORONE CAPROATE [MI]
Common Name English
Gestonorone caproate [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C776
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
Code System Code Type Description
CAS
1253-28-7
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
DRUG BANK
DB14677
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
FDA UNII
U38E620NS6
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
INN
2016
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
MESH
D005866
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
RXCUI
4791
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY RxNorm
EVMPD
SUB07902MIG
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
MERCK INDEX
m5718
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY Merck Index
NCI_THESAURUS
C74365
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
EPA CompTox
DTXSID40871837
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
ChEMBL
CHEMBL2107389
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
NSC
84054
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
WIKIPEDIA
Gestonorone caproate
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
ECHA (EC/EINECS)
215-010-2
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
SMS_ID
100000080396
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
DRUG CENTRAL
3261
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
PUBCHEM
443881
Created by admin on Mon Mar 31 17:47:11 GMT 2025 , Edited by admin on Mon Mar 31 17:47:11 GMT 2025
PRIMARY
Related Record Type Details
Structure of GESTADIENOL ACETATE
TARGET->ANALOGUE
Structure of METHENMADINONE CAPROATE
TARGET->ANALOGUE
Related Record Type Details
Structure of GESTONORONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966